Submitted by Anonymous (not verified) on 13 October 2023 - 10:24
Human medicines European public assessment report (EPAR): Ranivisio, ranibizumab, Wet Macular Degeneration;Macular Edema;Diabetic Retinopathy;Diabetes Complications, Date of authorisation: 25/08/2022, Revision: 4, Status: Authorised
Source: